M&A advisory for the diagnostic imaging, clinical lab, therapy, infusion, and specialty diagnostic platforms that anchor modern care delivery.
Outpatient MRI, CT, X-ray, PET, ultrasound, and mammography — shifting from hospital to outpatient settings.
Independent labs offering clinical, molecular, and pathology testing with strong margins at scale.
Outpatient rehabilitation across MSK, neuro, and pediatric conditions — highly fragmented and consolidating fast.
Home- and clinic-based infusion for oncology, autoimmune, and rare disease — strong commercial economics.
Home sleep testing and disorder management benefiting from chronic disease and awareness tailwinds.
NGS, pharmacogenomics, and precision testing — a high-growth, capital-attracting subsector.
Home-based care equipment riding care-at-home trends and post-acute referrals.
Sector intelligence covering market size, AI in diagnostics, recent transactions, and consolidation dynamics across radiology, lab, therapy, and ancillary services.